azol is a phosphodiesterase inhibitor that suppresses platelet aggregation and is also a direct vasodilator.
Patients can notice improvement in maximal and pain-free
walking distance in as short as 4 weeks.92 Other phosphodiesterase inhibitors have been noted to increase mortality in
patients with advanced heart failure; thus, cilostazol is contraindicated in patients with any level of heart failure. In addition to improving blood ï¬‚ow to the limb,